January 23, 2023
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses empagliflozin (Jardiance), 10 mg or 25 mg, orally administered film-coated tablets.
- Indication: Indicated in adults as an adjunct to standard-of-care therapy for the treatment of chronic heart failure.